-
- NEMOTO KYUICHI
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- HAYASHI MICHIKO
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- SUGAWARA YUMI
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- ITO JUNPEI
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- ABE FUMINORI
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- TAKITA TOMOHISA
- Research Laboratories, Pharmaceuticals Group, Nippon Kayaku Co., Ltd.
-
- NAKAMURA TERUYA
- Central Research Laboratories, Takara Shuzo Co., Ltd.
-
- TAKEUCHI TOMIO
- Institute of Microbial Chemistry
この論文をさがす
説明
An assessment of the prophylactic and ameliorative effects of deoxyspergualin (NKT-01), an immunosuppressive agent, was carried out in male MRL/MpJ-1pr/1pr (MRL/1) mice which spontaneously develop lupus-like lesions. When NKT-01 was administered ip daily from the age of either 8 or 19 weeks, diseases such as massive lymphadenopathy, circulating anti-DNA antibody and lupus nephritis were markedly suppressed. The primary response to lipopolysaccharide was significantly reduced in MRL/1 mice administered NKT-01 but the response to sheep red blood cells was not affected. The ability of spleen cells to release interleukins 2 and 3 with or without mitogen was significantly enhanced in mice receiving NKT-01. These findings demonstrate that NKT-01 has therapeutic activity against the development of spontaneous disease in MRL/1 mice.
収録刊行物
-
- The Journal of Antibiotics
-
The Journal of Antibiotics 41 (9), 1253-1259, 1988
公益財団法人 日本感染症医薬品協会